Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Serpin E2

Serpin E2

Brief Information

Name:Sodium channel protein type IX alpha subunit
Target Synonym:Voltage-Gated Sodium Channel Subunit Alpha Nav1.7,HNE-Na,PN1,Sodium Channel, Voltage Gated, Type IX Alpha Subunit,Neuroendocrine sodium channel,Sodium channel protein type IX subunit alpha,Peripheral sodium channel 1,Sodium channel protein type 9 subunit alpha,GEFSP7,HSAN2D,Nav1.7,FEB3B,NE-NA,ETHA,SFNP,NAV1.7 Voltage-Gated Sodium Channel,NENA,SCN9A,Sodium Voltage-Gated Channel Alpha Subunit 9,Sodium Channel, Voltage-Gated, Type IX, Alpha Polypeptide,Sodium Channel, Voltage-Gated, Type IX, Alpha
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:9
Lastest Research Phase:Approved

Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Tag:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
SE2-H5225 Human Human Serpin E2 / PN1 Protein, His Tag
SE2-H5225-structure
SE2-H5225-sds
ACRO Quality

Synonym Name

SERPINE2,Glia-derived nexin,GDN,Peptidase inhibitor 7,PI-7,Protease nexin 1,PN-1,Serpin E2,SerpinE2,PI7

Background

SERPINE2 is also known as Glia-derived nexin (GDN), Peptidase inhibitor 7 (PI7), Protease nexin 1(PN1). SERPINE2 is a secreted glycoprotein which belongs to the serpin family. SerpinE1 is the primary physiological inhibitor of the two plasminogen activators urokinase (uPA) and tissue plasminogen activator (tPA). PAI-1 / GDN is also implicated in adipose tissue development. It suggests that PAI-1 inhibitors serve in the control of atherothrombosis. Defects in Serpin E1 / PN1 are the cause of plasminogen activator inhibitor-1 deficiency (PAI-1 deficiency) which is characterized by abnormal bleeding due to SerpinE1 defect in the plasma.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Pirmenol Hydrochloride CI-845 Approved Pfizer Pharmaceuticals Ltd (China), Sumitomo Dainippon Pimavar, Pimenol Japan Arrhythmias, Cardiac null 1994-01-01 Arrhythmias, Cardiac Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Evenamide Hydrochloride NW-3509; NW-3509A Phase 3 Clinical Newron Pharmaceutical Schizophrenia; Mental Disorders Details
DWP-17061 iN1011-N17; DWP-17061 Phase 1 Clinical Daewoong Pharmaceutical Co Ltd Pain; Osteoarthritis Details
OLP-1002 OLP-1002 Phase 2 Clinical Olipass Co Osteoarthritis Details
BIIB-095 BIIB-095 Phase 1 Clinical Biogen Inc Diabetic Neuropathies Details
Funapide XPF-002; TV-45070; XEN 402; XPF 001; FX301; PCRX-301 Phase 1 Clinical Xenon Pharmaceuticals Inc Bunion; Pain, Postoperative; Neuralgia, Postherpetic; Erythromelalgia; Toothache; Osteoarthritis, Knee Details
Neu-P12 Neu-P12 Phase 1 Clinical Neurim Pharmaceuticals Ltd Neuralgia Details
DSP-3905 DSP-3905 Phase 1 Clinical Sumitomo Dainippon Pharma Co Ltd Neuralgia Details
PF-05089771 PF-5089771; PF-05089771 Phase 1 Clinical Pfizer Pharmaceuticals Ltd (China) Pain; Pain, Postoperative; Diabetic Neuropathies; Erythromelalgia Details
DSP-2230 DSP-2230; ANP-230 Phase 2 Clinical Sumitomo Dainippon Neuralgia Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message